Beyond Chemotherapy: Network Meta-Analysis Reveals Optimal Neoadjuvant Strategies for Luminal Breast Cancer.
Li Xinyu, Du Peijing, Huang Tao·Cancer medicine
BACKGROUND: Hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer represents the most common subtype. Given its distinct biology, neoadjuvant endocrine therapy (NET) offers comparable efficacy to neoadjuvant chemotherapy (NCT) with less toxicity. This systematic review and network meta-analysis evaluates…